In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Proteon (PRTO). The company’s shares opened today at $0.43, close to its 52-week low of $0.37.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.4% and a 41.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Molecular Templates Inc.
Currently, the analyst consensus on Proteon is a Hold with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.94 and a one-year low of $0.37. Currently, Proteon has an average volume of 1.19M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA.
